Alexandre Reuben

List of Publications by Year in Descending Order

87 papers	8,160 citations	35 h-index	90 g-index
109 ext. papers	11,894 ext. citations	12.9 avg, IF	5.51 L-index

#	Paper	IF	Citations
87	Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma.. *Journal of Experimental and Clinical Cancer Research*, **2022**, 41, 172	12.8	
86	Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. *Nature Communications*, **2021**, 12, 6655	17.4	1
85	Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer. *Annals of Oncology*, **2021**,	10.3	6
84	Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in -mutated melanoma. *OncoImmunology*, **2021**, 10, 1992880	7.2	2
83	Identification of bacteria-derived HLA-bound peptides in melanoma. *Nature*, **2021**, 592, 138-143	50.4	52
82	Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. *Immunity*, **2021**, 54, 586-602.e8	32.3	16
81	Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes. *Frontiers in Immunology*, **2021**, 12, 659625	8.4	0
80	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. *Journal of Thoracic Oncology*, **2021**, 16, 583-600	8.9	18
79	Intertumoral Genetic Heterogeneity Generates Distinct Tumor Microenvironments in a Novel Murine Synchronous Melanoma Model. *Cancers*, **2021**, 13,	6.6	1
78	Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. *Nature Communications*, **2021**, 12, 2722	17.4	16
77	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. *Nature Medicine*, **2021**, 27, 1432-1441	50.5	57
76	Augmented Lipocalin-2 Is Associated with Chronic Obstructive Pulmonary Disease and Counteracts Lung Adenocarcinoma Development. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 90-101	10.2	8
75	Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. *Journal of Thoracic Oncology*, **2021**, 16, 127-139	8.9	14
74	Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. *Nature Communications*, **2021**, 12, 687	17.4	9
73	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. *Nature Medicine*, **2021**, 27, 504-514	50.5	105
72	Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer **2021**, 9,		13
71	Multiomics Analysis Reveals Distinct Immunogenomic Features of Lung Cancer with Ground-Glass Opacity. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 204, 1180-1192	10.2	1

70	The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. *Nature Communications*, **2021**, 12, 7081	17.4	1
69	Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. *Genome Biology*, **2020**, 21, 271	18.3	13
68	Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort **2020**, 8,		13
67	Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. *Science Translational Medicine*, **2020**, 12,	17.5	54
66	Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. *Lung Cancer*, **2020**, 146, 303-309	5.9	2
65	Immuno-genomic landscape of osteosarcoma. *Nature Communications*, **2020**, 11, 1008	17.4	77
64	B cells and tertiary lymphoid structures promote immunotherapy response. *Nature*, **2020**, 577, 549-555	50.4	654
63	Discovery of a novel shared tumor antigen in human lung cancer.. *Journal of Clinical Oncology*, **2020**, 38, 3087-3087	2.2	
62	Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. *Journal of Thoracic Oncology*, **2020**, 15, 1449-1459	8.9	49
61	Comprehensive T cell repertoire characterization of non-small cell lung cancer. *Nature Communications*, **2020**, 11, 603	17.4	67
60	Immune and Circulating Tumor DNA Profiling After Radiation Treatment for Oligometastatic Non-Small Cell Lung Cancer: Translational Correlatives from a Mature Randomized Phase II Trial. *International Journal of Radiation Oncology Biology Physics*, **2020**, 106, 349-357	4	15
59	Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy. *Clinical Cancer Research*, **2020**, 26, 2908-2920	12.9	12
58	Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy **2020**, 8,		14
57	Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. *Cancer Immunology Research*, **2020**, 8, 1365-1380	12.5	13
56	Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. *Clinical Cancer Research*, **2020**, 26, 5477-5486	12.9	12
55	F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. *Cancer Immunology, Immunotherapy*, **2020**, 69, 1519-1534	7.4	11
54	T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma. *Journal of Investigative Dermatology*, **2020**, 140, 2146-2156.e4	4.3	9
53	Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. *Nature Communications*, **2020**, 11, 1839	17.4	9

52	Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. *Clinical Cancer Research*, **2020**, 26, 1258-1266	12.9	55
51	Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 22699-22709	11.5	119
50	A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma. *Clinical Cancer Research*, **2019**, 25, 6429-6442	12.9	30
49	PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2019**, 14, 1021-1031	8.9	46
48	Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. *Cancer Immunology Research*, **2019**, 7, 1025-1035	12.5	42
47	Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14 and CD16 monocytes driving an innate immune response. *Journal of Cutaneous Pathology*, **2019**, 46, 627-636	1.7	12
46	Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. *Nature Communications*, **2019**, 10, 2978	17.4	43
45	Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer. *Annals of Oncology*, **2019**, 30, 1521-1530	10.3	47
44	Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2019**, 37, 9017-9017	2.2	7
43	Association of relative neutrophilia with a distinct immunoinhibitory milieu in non-small cell lung cancer.. *Journal of Clinical Oncology*, **2019**, 37, e14047-e14047	2.2	0
42	Characterization of Changes in the T-Cell Receptor Repertoire in Patients with Acute Myeloid Leukemia with Durable Remission Following Allogeneic Stem Cell Transplant. *Blood*, **2019**, 134, 5186-5186	2.2	
41	Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. *Cancer Discovery*, **2019**, 9, 628-645	24.4	124
40	The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. *Cancer Cell*, **2018**, 33, 570-580	24.3	527
39	A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. *OncoImmunology*, **2018**, 7, e1423172	7.2	20
38	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. *Lancet Oncology, The*, **2018**, 19, 181-193	21.7	168
37	Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. *Science*, **2018**, 359, 97-103	33.3	1895
36	Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy. *Frontiers in Immunology*, **2018**, 9, 946	8.4	13
35	Association of the T-cell receptor landscape with survival in non-small cell lung cancer.. *Journal of Clinical Oncology*, **2018**, 36, 140-140	2.2	2

34	P2.04-09 Driver Mutations are Associated with Distinct Patterns of Response to Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2018**, 13, S733-S734	8.9	2
33	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. *Nature Medicine*, **2018**, 24, 1649-1654	50.5	377
32	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. *Cell*, **2018**, 175, 998-1013.e20	56.2	631
31	Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma. *Cancer Discovery*, **2018**, 8, 1366-1375	24.4	57
30	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. *Science Translational Medicine*, **2017**, 9,	17.5	409
29	An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. *Journal of Experimental Medicine*, **2017**, 214, 1691-1710	16.6	51
28	Gene Targeting Meets Cell-Based Therapy: Raising the Tail, or Merely a Whimper?. *Clinical Cancer Research*, **2017**, 23, 327-329	12.9	1
27	Interaction of molecular alterations with immune response in melanoma. *Cancer*, **2017**, 123, 2130-2142	6.4	18
26	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. *Npj Genomic Medicine*, **2017**, 2,	6.2	82
25	Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. *Science*, **2017**, 357, 1156-1160	33.3	577
24	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. *Cancer Discovery*, **2017**, 7, 1088-1097	24.4	105
23	Toward a Molecular-Genetic Classification of Spitzoid Neoplasms. *Clinics in Laboratory Medicine*, **2017**, 37, 431-448	2.1	25
22	Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. *OncoImmunology*, **2017**, 6, e1361097	7.2	31
21	Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. *OncoImmunology*, **2017**, 6, e1321187	7.2	32
20	The hemochromatosis protein HFE 20 years later: An emerging role in antigen presentation and in the immune system. *Immunity, Inflammation and Disease*, **2017**, 5, 218-232	2.4	24
19	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. *Cancer Discovery*, **2016**, 6, 827-37	24.4	561
18	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. *OncoImmunology*, **2016**, 5, e1136044	7.2	42
17	Targeted Therapies Combined With Immune Checkpoint Therapy. *Cancer Journal (Sudbury, Mass.)*, **2016**, 22, 138-46	2.2	24

16	Monitoring immune responses in the tumor microenvironment. *Current Opinion in Immunology*, **2016**, 41, 23-31	7.8	76
15	Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy. *Current Oncology Reports*, **2016**, 18, 42	6.3	36
14	Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. *JAMA Oncology*, **2016**, 2, 1056-64	13.4	34
13	Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma. *Clinical Cancer Research*, **2016**, 22, 5553-5563	12.9	70
12	Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. *Seminars in Oncology*, **2015**, 42, 601-16	5.5	83
11	Update on use of aldesleukin for treatment of high-risk metastatic melanoma. *ImmunoTargets and Therapy*, **2015**, 4, 79-89	9	14
10	Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy. *Clinical Cancer Research*, **2015**, 21, 3102-4	12.9	22
9	T lymphocyte-derived TNF and IFN-γ repress HFE expression in cancer cells. *Molecular Immunology*, **2015**, 65, 259-66	4.3	5
8	Raising the bar: optimizing combinations of targeted therapy and immunotherapy. *Annals of Translational Medicine*, **2015**, 3, 272	3.2	
7	The WT hemochromatosis protein HFE inhibits CD8+ T-lymphocyte activation. *European Journal of Immunology*, **2014**, 44, 1604-14	6.1	15
6	Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma. *OncoImmunology*, **2014**, 3, e954956	7.2	17
5	Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. *Cancer Biology and Medicine*, **2014**, 11, 237-46	5.2	57
4	Polyfunctionality of a DKK1 self-antigen-specific CD8(+) T lymphocyte clone in lung cancer. *Cancer Immunology, Immunotherapy*, **2011**, 60, 1119-25	7.4	1
3	Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by using a broth microdilution method. *Antimicrobial Agents and Chemotherapy*, **1989**, 33, 1647-9	5.9	75
2	Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features		2
1	Deep learning-based prediction of the T cell receptor–antigen binding specificity. *Nature Machine Intelligence*,	22.5	9